New combo shows promise for rare thymic cancer
NCT ID NCT04710628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a combination of two drugs, pembrolizumab and lenvatinib, in 43 people with advanced thymic carcinoma or a related thymoma that had worsened after standard chemotherapy. The goal was to see if the combination could stop or slow cancer growth. Participants received the drugs by mouth and through an IV, and researchers tracked how long they lived without their cancer getting worse.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. San Luigi Gonzaga
Orbassano, Italy
-
Centre Hospitalier Universitaire de Toulouse
Toulouse, France
-
Centre Oscar Lambert
Lille, France
-
Complejo Hospitalario Universitario A Coruña (CHUAC)
A Coruña, Spain
-
Hospital Clinic i Provincial de Barcelona
Barcelona, 08036, Spain
-
Hospital Sant Creu i Sant Pau
Barcelona, Spain
-
Hospital Universitari i Politècnic La Fe
Valencia, Spain
-
Hospital Universitario La Paz
Madrid, Spain
-
Hospital Universitario Virgen del Rocío
Seville, Spain
-
Hôpitaux Universitaires de Marseille - Hôpital Nord
Marseille, France
-
IGR Gustave Roussy
Villejuif, France
-
Institut Bergonié
Bordeaux, France
-
Institut Curie
Paris, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.